Sara El Ashkar
Janssen R&D
Beerse, VLG, Belgium
Beerse, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
Journal: Blood
Published: September 12, 2023
BET-Independent Murine Leukemia Virus Integration Is Retargeted In Vivo and Selects Distinct Genomic Elements for Lymphomagenesis.
Journal: Microbiology spectrum
Published: July 19, 2022
Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation.
Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 13, 2018
LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.
Journal: Blood
Published: May 26, 2017
Engineering Next-Generation BET-Independent MLV Vectors for Safer Gene Therapy.
Journal: Molecular therapy. Nucleic acids
Published: November 18, 2016
Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia.
Journal: Cancer research
Published: August 02, 2014
BET-independent MLV-based Vectors Target Away From Promoters and Regulatory Elements.
Journal: Molecular therapy. Nucleic acids
Published: March 14, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026